ReviewInternational journal of molecular sciences2023
The Critical Impact of Sphingolipid Metabolism in Breast Cancer Progression and Drug Response.
Review in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Exploratory Spatial Lipidomic Profiling Reveals Regional Metabolic Heterogeneity in a Canine Mixed Mammary Carcinoma.Veterinary sciences · 2026Article
- Metabolic Fingerprinting of Urine Reveals Metabolite Changes in Women With Breast Cancer.Cancer medicine · 2026Article
- An integrative approach to studying sphingolipid metabolism reveals p53 as a master regulator of the pathway.Journal of lipid research · 2026Article
- Plasma Sphingolipid Profiling Predicts Radiosensitivity in Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2026Article
- Mechanistic insights into daidzin from Glycine max against breast cancer via network pharmacology and multi-level molecular modeling.PloS one · 2026Article
- Article
- Deciphering the causal effects of plasma metabolomics and lipids on breast cancer risk: a Mendelian randomization analysis.Discover oncology · 2025Article
- Comparison of viscoelastic properties of breast cancer and normal cells using AFM, FLIM and ToF-SIMS techniques.Scientific reports · 2025Article
- JOINT IDENTIFICATION OF SPATIALLY VARIABLE GENES VIA A NETWORK-ASSISTED BAYESIAN REGULARIZATION APPROACH.The annals of applied statistics · 2025Article
- Lipidomic and transcriptomic analysis and its therapeutic implications in Chinese Kazakh patients with esophageal squamous cell carcinoma.BMC cancer · 2025Article
- Metabolomics as a tool for understanding and treating triple-negative breast cancer.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Lipid metabolites as biomarkers and therapeutic targets in oral squamous cell carcinoma.BMC oral health · 2025Article
- Machine learning-assisted quantitative metabolomics of West African patients with advanced breast cancer.Scientific reports · 2025Article
- Review
- Development and validation of a machine learning-driven mitochondrial gene signature for the diagnosis of breast cancer.Frontiers in immunology · 2025Article
- Altered metabolism in cancer: insights into energy pathways and therapeutic targets.Molecular cancer · 2024Review
- Biochemical Pathways Delivering Distinct Glycosphingolipid Patterns in MDA-MB-231 and MCF-7 Breast Cancer Cells.Current issues in molecular biology · 2024Review
- Decoding dynamic miRNA:ceRNA interactions unveils therapeutic insights and targets across predominant cancer landscapes.BioData mining · 2024Article
- Bee Venom Toxic Effect on MDA-MB-231 Breast Cancer Cells andAnti-cancer agents in medicinal chemistry · 2024Article
- Sphingomyelin Metabolism Modifies Luminal A Breast Cancer Cell Line under a High Dose of Vitamin C.International journal of molecular sciences · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer is the second leading cause of cancer-related death in women in the world, and its management includes a combination of surgery, radiation therapy, chemotherapy, and immunotherapy, whose effectiveness depends largely, but not exclusively, on the molecular subtype (Luminal A, Luminal B, HER2+ and Triple Negative). All breast cancer subtypes are accompanied by peculiar and substantial changes in sphingolipid metabolism. Alterations in sphingolipid metabolite levels, such as ceramides, dihydroceramide, sphingosine, sphingosine-1-phosphate, and sphingomyelin, as well as in their biosynthetic and catabolic enzymatic pathways, have emerged as molecular mechanisms by which breast cancer cells grow, respond to or escape therapeutic interventions and could take on diagnostic and prognostic value. In this review, we summarize the current landscape around two main themes: 1. sphingolipid metabolites, enzymes and transport proteins that have been found dysregulated in human breast cancer cells and/or tissues; 2. sphingolipid-driven mechanisms that allow breast cancer cells to respond to or evade therapies. Having a complete picture of the impact of the sphingolipid metabolism in the development and progression of breast cancer may provide an effective means to improve and personalize treatments and reduce associated drug resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.